Dear BMD,
Thanks for supplying update on Molnupiravir Antiviral which I read quite carefully (although not sure of relevance to BIT). However one sentence did jump out at me.
"The Company anticipates initial efficacy data in the first quarter of 2021, which Merck plans TO SHARE PUBLICLY IF CLINICALLY MEANINGFUL".
I take it this is the gold standard for big pharma to only publicly share positive outcomes & stay quiet about failures.
This debunks your earlier theory that "No news is good news "
All the best.
Not long now.
Scripps Research, page-31
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
